Pharmacokinetics and Safety of Olaparib in Patients with Advanced Solid Tumours and Renal Impairment.
Fiche publication
Date publication
mars 2019
Journal
Clinical pharmacokinetics
Auteurs
Lien Pubmed
Résumé
Olaparib, a potent oral poly(ADP-ribose) polymerase inhibitor, is partially renally cleared. We investigated the pharmacokinetics and safety of olaparib in patients with mild or moderate renal impairment to provide dosing recommendations.
Référence
Clin Pharmacokinet. 2019 Mar 16;: